Disclosed is a compound of formula (I) where R1 is acyl, X is an optionally substituted thiazole and the rest of the substituents are as disclosed in the specification. Examples of compounds of formula (I) are: 4-{ 2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl} phenyl hydrazinecarboxylate, 4-{ 2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl} benzyl hydrazinecarboxylate, and 2-(4-{ 2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl} phenyl) ethyl hydrazinecarboxylate. Also disclosed is a pharmaceutical composition, agent or VAP-1 inhibitor comprising a compound of formula (I) for treating conditions such as edema, juvenile rheumatoid arthritis, inflammatory disease and diabetic complications include eye diseases to name just a few. Further disclosed is the use of the compound of formula (I), or a pharmaceutically acceptable salt thereof, for the production of a pharmaceutical agent as a 5 VAP-1 inhibitor or for the prophylaxis or treatment of a VAP-1 associated disease.
